The potential of immunotherapy for solid tumors is confirmed by the approval of therapies targeting the programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) pathway for patients with recurrent/metastatic melanoma or mismatch repair–deficient cancers, among others (1–3). Here, PDCD1 is linked to metastatic melanoma.